Slide 1: TLANDO, Oral Testosterone Replacement Therapy without Dose Titration Requirement in Hypogonadal Men
AUA- Exhibit 99.1 2021 TLANDO™, Oral Testosterone Replacement Therapy without Dose Titration Requirement in Hypogonadal Men Kongnara Papangkorn’, Anthony DelConte’:2, Kilyoung Kim’, Benjamin Bruno’, Mohit Khera*, Nachiappan Chidambaram’, Mahesh Patel!’ ‘Lipocine Inc., Salt Lake City, UT; 2Saint Jose
Slide 2: Efficacy of Treatment with TLANDO
Efficacy of Treatment with TLANDO Oral Testosterone Undecanoate - 225 mg Twice Daily UPrimary & Secondary Efficacy Endpoints Proportion of Subjects Criteria Efficacy Target TLANDO™ Primary Efficacy T Cavg within normal range (300 — 1080 ng/L) BUS ees 95% Cl lower bound 265% 72% Secondary Efficacy <
Slide 3: Bioequivalent Exposure in Low, Med, or High Fat Food
Bioequivalent Exposure in Low, Med, or High Fat Food* Flexibility on Diet 1600 With Food Bioequivalent Exposure _ asoo -® Low fat a $ 1200 —e- Standard fat = —e— High fat 2g 1000 o bad e 800 2 3 600 Cc 3 = 400 7 Fasting Time (hr) LIPOCIN= * LPCN 1021-14-01 Study (Food/fat Study): N=14 hypogonadal ma
Slide 4: Effect of TLANDO on FSH and LH Levels
Effect of TLANDO on FSH and LH Levels* Minimal Impact on FSH and LH ¢ Most of the subjects had appreciable ¢ Substantial % of subjects were maintained levels of FSH and LH within normal range for FSH and LH at end of study 99% 70% 40% 41% FSH - FSH LH LIPOCIN= * Study NCT03242590 (N=95) ENHANCING HE
Slide 5: TLANDO Effect in Geriatric Subjects
TLANDO Effect in Geriatric Subjects Potential Benefits for Geriatric Population QO) Hypogonadal males of age >65 OU Mean Cavg and Cmax are Comparable between years in three Phase 3 studies Hypogonadal males of >65 and <65 years old QO Study NCT02081300: NCT02081300 NCT03242590 9 . = 10% of 210 subje
Slide 6: Effect of TLANDO on Systolic Blood Pressure and Hematocrit
Effect of TLANDO on Systolic Blood Pressure and Hematocrit Low Impact on Cardiovascular System * Study NCTO3868059 (ABPM Study) ¢ Change of Hematocrit from Baseline — Low incidence of Hematocrit > 54% observed SBP Change from BL to EOS (mmHg) in all the TLANDO clinical studies Overall SBP > 140 mmHg
Slide 7: Summary & Conclusions
AUA: 2021 Summary & Conclusions * Safety and efficacy of TTANDO™ (Oral Testosterone Undecanoate) was confirmed * TLANDO™ is a novel oral TRT option without requiring dose titration * Start of therapy with the effective dose without delay * No additional dose adjustment visits ¢ Potential to improve